PANRESISTANT SUPERBUGS: ARE WE AT THE EDGE OF A ‘MICROBIAL HOLOCAUST’
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2017.2.8012Keywords:
Panresistance, Antimicrobial Resistance, Totally Drug Resistant Tuberculosis, Infection Control, Antimicrobial Stewardship.Abstract
Contemporary healthcare has progressed towards world health security through advancements in medication-based and surgical interventions, supported by the success of antimicrobial therapy. The emergence of panresistant infectious diseases is becoming a public health problem worldwide. Panresistance is attributable to a complex interplay of antimicrobial overuse in healthcare facilities due to lack of regulatory commitment in the backdrop of natural mutations in pathogens and rise in immunocompromised hosts. Developing countries are facing the brunt in epidemic proportions due to strained public health infrastructure and limited resource allocation to healthcare. Panresistance is a biological, behavioural, technical, economic, regulatory and educational problem of global concern and combating it will require concerted efforts to preserve the efficacy of the available antimicrobials. An intensified commitment needs to be taken up on a war footing to increase awareness in the society, increase laboratory capacity, facilitate antimicrobial research, foster emphasis on infection control and antimicrobial stewardship, and legislation on manufacturing, marketing and dispensing of antimicrobials.
References
Khan ID, Sahni AK, Bharadwaj R, Lall M, Jindal AK, Sashindran VK. Emerging Organisms in a Tertiary Healthcare Set Up. Med J Armed Forces India. 2014;70(2):120–128.
World Health Organization. World Health Day 2011: policy briefs. Geneva, WHO, 2011. http://www.who.int/world-health-day/2011/policybriefs/en/index.html. Accessed 20 Jun 2017.
Jindal AK, Pandya K, Khan ID. Antimicrobial Resistance: A public health challenge. Med J Armed Forces India. 2014;71(2):178–181. doi:10.1016/j.mjafi.2014.04.011.
Vijayvergia V, Sahni AK, Lal M, Vijay K, Khan ID. Phenotypic detection of ESBL and Amp C Beta-Lactamases in a tertiary care hospital. Bang J Med Sci. 2013;12(4):378–384.
Khan ID, Mukherjee T, Gupta S, Haleem S, Sahni AK, Banerjee S, et al. Ochrobactrum anthropi sepsis in intensive tertiary care. J Basic & Clin Med. 2014;3(1):18–20.
Khan ID, Lall M, Sen S, Ninawe SM, Chandola P. Multiresistant Elizabethkingia meningoseptica Infections in Tertiary Care. Med J Armed Forces India. 2014;71(3):66–67. doi:10.1016/j.mjafi.2014.02.002.
Khan ID, Sati A, Arif S, Mehdi I, Bhatt P, Jain V, et al. Streptococcus mitis/oralis Corneal Ulcer after Corneal Transplantation. J Basic & Clin Med. 2016;5(1):8–10.
Sheu TG, Fry AM, Garten RJ, Deyde VM, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A (H1N1) viruses: 2008-2010. J Infect Dis. 2010;203:13–7.
Fraser GL, Stogsdill P, Dickens JD, et al. Antibiotic optimization: An evaluation of patient safety and economic outcomes. Arch Intern Med. 1997;157:1689–94.
Pelletier LL. Hospital usage of parenteral antimicrobial agents: a gradated utilization review and cost containment program. Infect Control. 1985;6(6):226–30.
Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005;5:24–8.
Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug resistant tuberculosis in India. Clin Infec Dis. 2011. Doi:10.1093/cid/cir8898.
Mahadev B, Kumar P, Agarwal SP, Chauhan LS, Srikantaramu N. Surveillance of drug resistance to anti-tuberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa. Indian J Tuberc. 2005:52(1);5–10.
Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill. 2007;12(20):3194.
Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli: Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran. Chest. 2009;136(2):420–425.
Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009;13(8):976–81.
Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malaria J. 2009;8:31.
Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug resistant malaria. Science Direct. 2002;2(4):209–18.
Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ. Antimalarial drug resistance: Literature review and Activities and Findings of the ICEMR network. The American Journal of Tropical Medicine and Hygiene. 2015;93:57–68. https://doi:10.4269/ajtmh.15-0007.
Michele MT, Ghany MG. Hepatitis B virus treatment: Management of Antiviral drug resistance. Clinical Liver Disease. 2013;2(1):24–28. Doi: 10/1002/cld.162.
Pillay D, Zambon M. Antiviral drug resistance. BMJ 1998;5:317(7159):660–662.
Sellar RS, Peggs KS. Management of multidrug resistant viruses in the immunocompromised host. British Journal of Haematology. 2012;156:559–72. doi: 10.1111/j.1365-2141.2011.08988.x.
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–94.
World Economic Forum. Report on Global Risks. Geneva: WEF; 2013. http://qfc.de/qfc.de/uploads/media/WEF_ GlobalRisks_Report_2013Teil2.pdf. Accessed 20 Jun 2017.
Spellberg B, Guidos R, Gilbert D et al. The Epidemic of Antibiotic-Resistant Infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infec Dis. 2008:46(2);155–164.
World Health Organization. Antimicrobial resistance: revisiting the “tragedy of the commons”. http://www.who.int/bulletin/volumes/88/11/10-031110/en/index.html. Accessed 20 Jun 2017.
Ghafur A, Mathai D, Muruganathan A, et al. "The Chennai Declaration“. "A roadmap- to tackle the challenge of antimicrobial resistance" - A joint meeting of medical societies of India. Indian J. Cancer. http://www.indianjcancer.com/preprintarticle.asp?id=104065.
Chang MT, Wu TH, Wang CY, et al. The impact of an intensive antimicrobial control program in a Taiwanese medical center. Pharm World Sci. 2006;28:257–264.
Apisarnthanarak A, Danchaivijitr S, Khawcharoenporn T, Limsrivilai J, Warachan B, Bailey TC, et al. Effectiveness of education and an antibiotic-control program in a tertiary care hospital in Thailand. Clin Infect Dis. 2006;42:768–75.
World Health Organization. WHO Model list of Essential Medicines. 20th List (March 2017). http://www.who.int.medicines/publications/essentialmedicines/en/. Accessed 20 Jun 2017.
Katz R, Fischer J. The Revised International Health Regulations: A Framework for Global Pandemic Response. http://www.ghgj.org/Katz%20and%20Fischer_ The%20Revised %20International%20Health%20Regulations.pdf. Accessed 20 Jun 2017.
NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Atlanta, GA: Centers for Disease Control and Prevention, Department of Health and Human Services; 2004. http://www.cdc.gov. Accessed 20 Jun 2017.
Carlet J, Rambaud C, Pulcini C. WAAR (World Alliance against Antibiotic Resistance): Safeguarding antibiotics. Antimicrob Resist Infect Control. 2012;1:25.
World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics. http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/. Accessed 01 Sep 2017.
World Health Organization. WHO Model List of Essential Medicines. 20th List. Mar 2017. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 01 Sep 2017.
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
